AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine ... rivals Pfizer/BioHaven and their recently-approved Vydura drug.

The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

The Department of Justice (DoJ) claims that Biohaven – before being ... than $1.8 billion last year. The drug is approved both to treat and prevent migraine in adults and is one of the top ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Biohaven's antibody drug conjugate (ADC ... advancing enrollment in proof of concept trial with BHV-2100 in acute migraine; data from the laser-evoked potential study expected in 1H 2025.

TRPM3 Ion Channel Antagonism: Migraine & Neuropathic Pain BHV ... ADC Platform - Milestones and Next Steps: Biohaven's antibody drug conjugate (ADC) technology is focused on novel, modular ...

Apart from the mega $43 billion deal for oncology pioneer Seagan in 2023, the deals included the $11.6 billion acquisition of migraine drug maker Biohaven Pharmaceutical Holding Co. Ltd and the $5 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

has settled a lawsuit against a Pfizer subsidiary for illegal kickbacks to physicians for prescribing migraine drugs. Biohaven is the pharmaceutical company that was being sued for allegedly holding ...